Theravance Biopharma (FRA:0TB) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
71 GF Score
Price €14.50
GF Value €14.63
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Theravance Biopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Theravance Biopharma Quality Rank Related Terms

FRA:0TB
71GF Score
Theravance Biopharma Inc FRA:0TB
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.50 is trading 0.9% below its estimated GF Value™ of €14.63. GuruFocus considers Theravance Biopharma to be Fairly Valued.

Key valuation signals for FRA:0TB:

  • Quality Rank:
  • GF Value™: €14.63 vs. price of €14.50 (0.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
71GF Score

Get the complete analysis for FRA:0TB

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.50
Price
€14.63
GF Value